NewLimit raises $435M Series C led by Founders Fund to bring longevity medicines to human trials
What's the deal? NewLimit, a longevity-focused biotech building epigenetic reprogramming medicines, has closed a $435M Series C at a $3.1B valuation. The round is led by Founders Fund, with new investors Thrive Capital, Greenoaks and Quiet Capital joining returning backers Kleiner Perkins, Abstract Ventures, Nat FriedmanDealroom has a profile for this one. Try Dealroom →, Daniel GrossDealroom has a profile for this one. Try Dealroom →, Valor Equity Partners, Lilly VenturesDealroom has a profile for this one. Try Dealroom → and Human CapitalDealroom has a profile for this one. Try Dealroom →.
Why now? NewLimit plans to begin its first human clinical trial in 2027, on a prototype medicine that reverses cell age in old human liver cells. The company says the therapy could help livers heal faster after injury, resist damage from dietary stress and accelerate recovery from alcohol consumption. The accelerated path to trial — from a company that initially thought it would take more than a decade — is what unlocked this round.
What could go wrong? Longevity biotech remains a high-risk bet. Regulatory pathways for age-reversal therapies are uncharted, and translating cellular results into approved medicines can take years — or fail entirely. A tripled valuation also raises the stakes for future rounds and eventual returns.
The signal: NewLimit was founded in 2021 by Brian ArmstrongDealroom has a profile for this one. Try Dealroom → (CEO of Coinbase), former GV partner Blake ByersDealroom has a profile for this one. Try Dealroom →, and computational biologist Jacob KimmelDealroom has a profile for this one. Try Dealroom →, who serves as CEO. A Founders Fund-led Series C at a $3.1B mark signals that capital in longevity is concentrating around companies with a concrete therapeutic thesis and a near-term clinical readout, rather than spreading thinly across the broader anti-ageing landscape.
Read more: NewLimit blog · Investing.com
